吉西他滨或S-1治疗不可切除胰腺癌患者生存的实用预后指数。

Hepato-gastroenterology Pub Date : 2015-03-01
Tatsuya Kurihara, Mari Kogo, Masakazu Ishii, Keiichiro Yoneyama, Katsuya Kitamura, Ken Shimada, Shunichi Shimizu, Hitoshi Yoshida, Yuji Kiuchi
{"title":"吉西他滨或S-1治疗不可切除胰腺癌患者生存的实用预后指数。","authors":"Tatsuya Kurihara,&nbsp;Mari Kogo,&nbsp;Masakazu Ishii,&nbsp;Keiichiro Yoneyama,&nbsp;Katsuya Kitamura,&nbsp;Ken Shimada,&nbsp;Shunichi Shimizu,&nbsp;Hitoshi Yoshida,&nbsp;Yuji Kiuchi","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aims: </strong>We performed this retrospective cohort study to identify prognostic factors for unresectable pancreatic cancer treated with current standard therapy using gemcitabine (GEM) or S-1 and to stratify patients prior to treatment using a prognostic index (PI).</p><p><strong>Methodology: </strong>We analyzed 182 patients with unresectable pancreatic cancer, who had received GEM or S-1 as first-line chemotherapy. Factors that contributed to the prognosis were identified by univariate and multivariate analysis using a Cox proportional hazards model. The PI was constructed using the factors identified in the multivariate analysis.</p><p><strong>Results: </strong>By multivariate analysis, performance status (PS), stage, and absolute neutrophil count (ANC) were identified as factors that independently contributed to the prognosis of unresectable pancreatic cancer (P < 0.05). The hazard ratios were 1.69, 3.33, and 1.18, respectively. In addition, PI was calculated using these three factors. Patients were classified into three groups according to the PI values. A significant difference was observed among the survival curves of these three groups (P < 0.05).</p><p><strong>Conclusions: </strong>We identified three prognostic factors in the population after the introduction of S-1, and have created a simple and useful PI. This index demonstrates the ability to accurately classify advanced pancreatic cancer patients before the start of treatment.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 138","pages":"478-84"},"PeriodicalIF":0.0000,"publicationDate":"2015-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Practical prognostic index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1.\",\"authors\":\"Tatsuya Kurihara,&nbsp;Mari Kogo,&nbsp;Masakazu Ishii,&nbsp;Keiichiro Yoneyama,&nbsp;Katsuya Kitamura,&nbsp;Ken Shimada,&nbsp;Shunichi Shimizu,&nbsp;Hitoshi Yoshida,&nbsp;Yuji Kiuchi\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aims: </strong>We performed this retrospective cohort study to identify prognostic factors for unresectable pancreatic cancer treated with current standard therapy using gemcitabine (GEM) or S-1 and to stratify patients prior to treatment using a prognostic index (PI).</p><p><strong>Methodology: </strong>We analyzed 182 patients with unresectable pancreatic cancer, who had received GEM or S-1 as first-line chemotherapy. Factors that contributed to the prognosis were identified by univariate and multivariate analysis using a Cox proportional hazards model. The PI was constructed using the factors identified in the multivariate analysis.</p><p><strong>Results: </strong>By multivariate analysis, performance status (PS), stage, and absolute neutrophil count (ANC) were identified as factors that independently contributed to the prognosis of unresectable pancreatic cancer (P < 0.05). The hazard ratios were 1.69, 3.33, and 1.18, respectively. In addition, PI was calculated using these three factors. Patients were classified into three groups according to the PI values. A significant difference was observed among the survival curves of these three groups (P < 0.05).</p><p><strong>Conclusions: </strong>We identified three prognostic factors in the population after the introduction of S-1, and have created a simple and useful PI. This index demonstrates the ability to accurately classify advanced pancreatic cancer patients before the start of treatment.</p>\",\"PeriodicalId\":12985,\"journal\":{\"name\":\"Hepato-gastroenterology\",\"volume\":\"62 138\",\"pages\":\"478-84\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepato-gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepato-gastroenterology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景/目的:我们进行了这项回顾性队列研究,以确定目前使用吉西他滨(GEM)或S-1标准治疗的不可切除胰腺癌的预后因素,并在治疗前使用预后指数(PI)对患者进行分层。方法:我们分析了182例不能切除的胰腺癌患者,他们接受了GEM或S-1作为一线化疗。采用Cox比例风险模型,通过单因素和多因素分析确定影响预后的因素。使用多变量分析中确定的因素构建PI。结果:通过多因素分析,性能状态(performance status, PS)、分期、绝对中性粒细胞计数(absolute neutropil count, ANC)是影响不可切除胰腺癌预后的独立因素(P < 0.05)。风险比分别为1.69、3.33和1.18。此外,利用这三个因素计算PI。根据PI值将患者分为三组。三组患者的生存曲线比较差异有统计学意义(P < 0.05)。结论:我们在引入S-1后确定了人群中的三个预后因素,并创建了一个简单而有用的PI。该指标显示了在治疗开始前对晚期胰腺癌患者进行准确分类的能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Practical prognostic index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1.

Background/aims: We performed this retrospective cohort study to identify prognostic factors for unresectable pancreatic cancer treated with current standard therapy using gemcitabine (GEM) or S-1 and to stratify patients prior to treatment using a prognostic index (PI).

Methodology: We analyzed 182 patients with unresectable pancreatic cancer, who had received GEM or S-1 as first-line chemotherapy. Factors that contributed to the prognosis were identified by univariate and multivariate analysis using a Cox proportional hazards model. The PI was constructed using the factors identified in the multivariate analysis.

Results: By multivariate analysis, performance status (PS), stage, and absolute neutrophil count (ANC) were identified as factors that independently contributed to the prognosis of unresectable pancreatic cancer (P < 0.05). The hazard ratios were 1.69, 3.33, and 1.18, respectively. In addition, PI was calculated using these three factors. Patients were classified into three groups according to the PI values. A significant difference was observed among the survival curves of these three groups (P < 0.05).

Conclusions: We identified three prognostic factors in the population after the introduction of S-1, and have created a simple and useful PI. This index demonstrates the ability to accurately classify advanced pancreatic cancer patients before the start of treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hepato-gastroenterology
Hepato-gastroenterology 医学-外科
自引率
0.00%
发文量
1
审稿时长
1.9 months
期刊介绍: Hepato-Gastroenterology has been discontinued as of 2015. Extremely limited quantities of back issues in print available for sale.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信